Home › Funds › BML Capital Management, LLC › JANX
BML Capital Management, LLC position in JANX
JANUX THERAPEUTICS INC · Health Care
BML Capital Management, LLC reported holding 151,126 shares of JANX (JANUX THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 1.39% of its reported portfolio and ranking #14 among its reported holdings. BML Capital Management, LLC has disclosed JANX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How BML Capital Management, LLC's JANX position evolved
BML Capital Management, LLC first disclosed a stake in JANX in Q1 2026 at 154,961 shares (US$2.2M). The position peaked in Q3 2026 at 151,126 shares, worth US$2.6M. Across 3 filings, BML Capital Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 151,126 shares valued at US$2.6M — a reduction of -3,835 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 154.96K | $2.15M | New |
| Q2 2026 | 154.96K | $2.38M | Hold |
| Q3 2026 | 151.13K | $2.61M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JANX and 13F data
JANX (JANUX THERAPEUTICS INC) is a Health Care company. 27 other funds we track also report a position in JANX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$171.9M), Prosight Management, LP (US$58.4M), TCG Crossover Management, LLC (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JANX
- RA CAPITAL MANAGEMENT, L.P. 11.19M sh · $171.87M · Q2 2026
- Prosight Management, LP 3.80M sh · $58.44M · Q2 2026
- TCG Crossover Management, LLC 1.79M sh · $27.49M · Q2 2026
More on BML Capital Management, LLC
FAQ
How long has BML Capital Management, LLC held JANX?
BML Capital Management, LLC has disclosed JANX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is BML Capital Management, LLC's current position in JANX?
As of Q3 2026, BML Capital Management, LLC holds 151.13K shares of JANX (JANUX THERAPEUTICS INC), valued at $2.61M, representing 1.39% of its reported portfolio and ranking #14.
Has BML Capital Management, LLC been buying or selling JANX?
In the latest 13F filing (Q3 2026), BML Capital Management, LLC reduced its position in JANX. The position peaked in Q3 2026 at 151.13K shares.
Which other funds hold JANX?
Other major institutional holders of JANX include RA CAPITAL MANAGEMENT, L.P., Prosight Management, LP, TCG Crossover Management, LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.